Back to News
Amgen's Imdelltra, paired with AstraZeneca's Imfinzi, cut the risk of death by 58% in patients with advanced lung cancer. The report provides no further trial details or information on regulatory status.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
AMGN0.80
AZN0.80
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Weekly earnings outlook: mega-cap tech, AI hardware and healthcare in focus
- UBS downgrades Roche stock rating to neutral on valuation concerns
- Tuesday's big stock stories: What’s likely to move the market in the next trading session
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- RA Capital Management sells $9.13M in Lenz Therapeutics shares